Axcella Health Inc.
Axcella Health Inc. (AXLA): 4 pipeline candidates · ~3 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.1 months
D/E -5.11 · 0% dilution
Lead: Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for Axcella Health Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$8.9M
Quarterly Burn
$8.8M
Runway
3.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| axa1125 | Phase 2 |
| axa1665 | Phase 2 |
| axa1957 | Phase 2 |
| nxc-201 car-t | Phase 1/Phase 2 |
Frequently asked questions
How many drug candidates are in Axcella Health Inc.'s pipeline?
Axcella Health Inc. (AXLA) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Axcella Health Inc.'s lead drug candidate?
Axcella Health Inc.'s most advanced tracked candidate is axa1125 (Phase 2) for NASH.
What is Axcella Health Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Axcella Health Inc. has approximately 3.1 months of cash runway.
Who is the CEO of Axcella Health Inc.?
Craig R. Jalbert Craig is the chief executive officer of Axcella Health Inc. (AXLA).
Get the full picture on Axcella Health Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.